Retatrutide Cost: Real Prices Per Milligram From Live Listings

Retatrutide has no pharmacy price because it has no approved product. It is an investigational drug in phase 3 development, so there is no list price, no insurance code and no legitimate retail channel. Every price quoted online comes from the research-chemical market.

That market is measurable, and the figures below come from listings tracked by Peptide Library.

What the research channel charges

Translating that into a monthly figure

Retatrutide is dosed weekly in trials, and the phase 2 programme tested a dose range rather than a single figure. Monthly cost therefore depends heavily on which dose is being modelled:

How it compares

Retatrutide is mid-range per milligram, which is notable given it is the newest of the four. Newer compounds usually carry a scarcity premium; cagrilintide still does. Retatrutide’s supply appears to have caught up faster, likely reflecting how much attention its phase 2 results attracted.

What the price does not include

The per-milligram figure is the narrowest possible view of cost. The rest of it:

• Bacteriostatic water, syringes, swabs — modest, but the cost guide itemises them.

• Independent testing — frequently more than the vial itself. See the testing labs guide.

• Wastage from vials that exceed the 28-day bacteriostatic water limit before being finished.

• No clinical monitoring, which is a cost the approved-drug price includes and this one does not.

Why cheap listings warrant a closer look

A listing well below the 10th percentile is not automatically fraudulent, and it is a reason to check four things: stated vial size against the COA, whether a batch-specific COA exists at all, whether mass spectrometry confirms identity rather than HPLC purity alone, and whether the product is what it claims to be.

Retatrutide is a particularly attractive target for substitution because it is expensive, in demand, and indistinguishable by eye from any other white lyophilised powder. The COA reading guide covers verification.

The status that sits behind the price

Retatrutide is not approved anywhere. Its phase 2 obesity results were published in the New England Journal of Medicine and a 2026 Lancet report covers type 2 diabetes, but publication is not approval and the phase 3 programme is ongoing.

See is retatrutide FDA approved and how to get retatrutide.